Sexual wellness
Effects of Kisspeptin Administration in Women With Hypoactive Sexual Desire Disorder: A Randomized Clinical Trial
Thurston L, Hunjan T, Mills EG, et al. · JAMA Netw Open · 2022
PMID: 36287566 · DOI: 10.1001/jamanetworkopen.2022.36131
Summary
Randomized double-blind placebo-controlled crossover trial of intravenous kisspeptin-54 in 32 premenopausal women with HSDD. Endpoints: task-based fMRI BOLD responses to sexual stimuli, sexual response scales.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →KisspeptinGPR54 agonist decapeptide studied in HPG-axis and reproductive-research models.
Guides covering this compound
More Sexual wellness citations
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsObstet Gynecol · 2019
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstet Gynecol · 2019
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionInt J Impot Res · 2004